Dr. Cora Sternberg discusses data from the Card study in patients with metastatic castration-resistant prostate cancer (mCRPC).
Cora Sternberg is the last author on this practice changing study. This study is important because it highlights the need to provide an accurate radiological monitoring, added to PSA tests, during the follow-up of patients with metastatic hormone-sensitive prostate cancer or nonmetastatic castration-resistant prostate cancer receiving enzalutamide treatment.
Excellence in the Cancer Therapeutics Research Program: Cora Sternberg honored in Research.com's 2025 global ranking.
Artificial intelligence (AI) has the potential to transform cancer therapeutic decision-making by improving diagnostics and personalizing treatments.
In the first episode of Precision Signals, a new podcast from the CEO Roundtable on Cancer, Dr. Sean Khozin speaks with Dr. Cora Sternberg and Dr. Olivier Elemento - two leaders at the intersection of clinical trials, precision medicine, and computational biology.
Is There Sufficient Evidence to Intensify Systemic Therapy in Patients With Prostate Cancer Who Have M1 by PSMA-PET but Negative Conventional Imaging?
ESMO 2024: Cora Sternberg video interview about her presentation on event-free survival (EFS) as a surrogate endpoint for overall survival in muscle-invasive bladder cancer.
This project received funding from the European Research Council (ERC) and from the Samuel and Barbara Sternberg Foundation.
The INSIDE-PC study provides evidence of the potential of AI systems in medical literature searches on complex clinical questions.
ESMO Congress 2024 - European Society for Medical Oncology Barcellona 13-17 Settembre 2024
In this video Cora Sternberg talks about efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel by disease, volume and risk in the phase three Arasens study.
In this video Dr. Cora Sternberg discusses new developments in the treatment of urothelial carcinoma.
In this interview for UroToday dr. Cora Sternberg presents the latest data and ongoing clinical trials in the context of prostate cancer.
